Lisa R. Fries, N. Khaled, Ivan Viveros Santos, Elvira Suniega-Tolentino, Motshewa Sesing, Melissa P. S. Toh, Chui Yuen Yang, Shiao-Yng Chan et Sara Colombo Mottaz
Article de revue (2025)
 Document en libre accès dans PolyPublie et chez l'éditeur officiel |
|
Libre accès au plein texte de ce document Version officielle de l'éditeur Conditions d'utilisation: Creative Commons: Attribution (CC BY) Télécharger (1MB) |
Abstract
Introduction: Novel technologies have enabled the decentralization of many aspects of clinical trials, but little research has been done on the impact of these changes on the participant experience, trial operations, or the environment.
Methods: A fully decentralized clinical trial conducted in Singapore is used as a case study to evaluate the operational outcomes, environmental impact (via life cycle assessment), and participants experience (qualitative interviews) of the decentralized model compared to a traditional study with in-person visits.
Results: The decentralized study achieved high participant retention rates (97%) and high completion rates for clinical data, even for biological samples. Participants found the decentralized model to be convenient and safe, especially during the pandemic. Moreover, the decentralized model was found to be more environmentally friendly and less detrimental to human health compared to traditional face-to-face clinical trials, primarily by reducing participants’ use of cars for site visits.
Discussion: While this study focused on the environmental impact, it is important to consider other factors such as participant safety, convenience, and data quality when evaluating the suitability of a decentralized clinical trial approach. Careful planning of data flow, database structure, and data protection measures is essential. This study contributes to improving the environmental footprint of clinical trials. Environmental sustainability should be among the factors that are evaluated when selecting trial models. Decentralized and hybrid clinical trials offer efficiency, effectiveness, and environmental benefits. Further research and adoption of these approaches are encouraged.
Mots clés
| Renseignements supplémentaires: | Le matériel supplémentaire n'est pas disponible présentement. |
|---|---|
| Département: | Département de génie chimique |
| Centre de recherche: | CIRAIG - Centre international de référence sur le cycle de vie des produits, procédés et services |
| Organismes subventionnaires: | Singapore Institute of Clinical Sciences, Agency for Science, Technology and Research, Nestlé (Singapore), Nestlé (Switzerland) |
| URL de PolyPublie: | https://publications.polymtl.ca/61974/ |
| Titre de la revue: | Frontiers in Public Health (vol. 12) |
| Maison d'édition: | Frontiers Media SA |
| DOI: | 10.3389/fpubh.2024.1508166 |
| URL officielle: | https://doi.org/10.3389/fpubh.2024.1508166 |
| Date du dépôt: | 16 janv. 2025 15:18 |
| Dernière modification: | 23 oct. 2025 22:04 |
| Citer en APA 7: | Fries, L. R., Khaled, N., Viveros Santos, I., Suniega-Tolentino, E., Sesing, M., Toh, M. P. S., Yang, C. Y., Chan, S.-Y., & Mottaz, S. C. (2025). Decentralized clinical trials are better for the participants and for the planet: the case study of a double-blind randomized controlled trial in Singapore (PROMOTE study). Frontiers in Public Health, 12, 14 pages. https://doi.org/10.3389/fpubh.2024.1508166 |
|---|---|
Statistiques
Total des téléchargements à partir de PolyPublie
Téléchargements par année
Provenance des téléchargements
Dimensions
Actions réservées au personnel
|
Afficher document |
